| |
Oxidized lipids enhance RANKL production by T lymphocytes: Implications for lipid-induced bone loss - pdf attached
|
| |
| |
Download the PDF here
Clinical Immunology Aug 17 2009
Article in Press, Corrected Proof
Lucia S. Grahama, Farhad Parhamib, Yin Tintutb, Christina M.R. Kitchenc, Linda L. Demerb and Rita B. Effrosa, Corresponding Author Contact Information, E-mail The Corresponding Author
aDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, 10833 Le Conte Avenue, Los Angeles, CA 90095-1732, USA
bDepartment of Medicine, David Geffen School of Medicine at UCLA, USA
cDepartment of Biostatistics, UCLA School of Public Health, USA
"These observations support a role for oxidized lipids in immune-mediated bone loss, and provide a possible mechanistic link for the well-documented association between dyslipidemia and osteoporosis......Epidemiological analyses have repeatedly shown associations between osteoporosis and hyperlipidemia [16], [17], [18], [19], [20], [21] and [22], and patients with lower bone density and osteoporosis have higher lipid levels, more severe coronary atherosclerosis and increased risk of stroke [18], [20], [23], [24] and [25]. Conversely, lipid-lowering treatments are associated with both reduced coronary vascular calcification [26] and fewer osteoporotic fractures [27], [28], [29] and [30] R.G. Schlienger, M.E. Kraenzlin, S.S. Jick and C.R. Meier, Use of beta-blockers and risk of fractures, JAMA 292 (2004), pp. 1326-1332. View Record in Scopus | Cited By in Scopus (92)[30]."
Unexpectedly, even in the absence of an activation stimulus, exposure of T lymphocytes to MM-LDL resulted in a significant increase in RANKL production (Fig. 1E). Indeed, this pattern was seen in T lymphocytes from all 15 healthy individuals tested, with fold-increases (over buffer alone) ranging from 4 to 55, and a mean fold-increase of 16 (Fig. 1F). The effect of MM-LDL on unstimulated T lymphocyte RANKL production was significantly greater than that of nLDL, which had only a modest effect
the in vitro data on human T lymphocytes, and the murine in vivo model of hyperlipidemia-induced bone loss indicate that exposure to oxidized lipids enhances T lymphocyte RANKL production. In parallel with our in vitro experiments on human T lymphocytes, we evaluated an in vivo model of bone loss induced in C57BL/6 mice that become hyperlipidemic when treated with a high-fat diet [41]. Consistent with our earlier studies [41], pQCT analysis of femoral bones from high-fat fed mice showed a significant reduction in bone mineral content compared to their chow-fed counterparts (Table 1). Importantly, T lymphocytes from these mice, tested immediately ex vivo, in the absence of any stimulation, expressed RANKL mRNA that was significantly greater than that of T lymphocytes from the chow-fed mice. The hyperlipidemic mice also had significant increases in serum levels of RANKL protein
"It has been well-established that chronic immune activation plays a key role in bone homeostasis. Indeed, skeletal changes are observed in a variety of clinical situations involving chronic, long-term immune activation. For example, reduced bone mass is being increasingly reported in HIV/AIDS, even in the absence of anti-retroviral drugs [78]. RANKL production by activated T lymphocytes has also been shown to play a central role in inflammatory bone loss, particularly in rheumatoid arthritis. The current study provides the first demonstration that not only activated, but also resting, unstimulated T lymphocytes are potential sources of RANKL, if they are exposed to oxidized lipids. In summary, our results underscore the interaction between T lymphocytes and oxidized lipids in osteoporosis and osteopenia, and provide a possible pathway for the documented improved bone mass seen in patients who are treated with lipid-lowering medications [26] and [28]."
Abstract
Osteoporosis is a systemic disease that is associated with increased morbidity, mortality and health care costs. Whereas osteoclasts and osteoblasts are the main regulators of bone homeostasis, recent studies underscore a key role for the immune system, particularly via activation-induced T lymphocyte production of receptor activator of NFκB ligand (RANKL). Well-documented as a mediator of T lymphocyte/dendritic cell interactions, RANKL also stimulates the maturation and activation of bone-resorbing osteoclasts. Given that lipid oxidation products mediate inflammatory and metabolic disorders such as osteoporosis and atherosclerosis, and since oxidized lipids affect several T lymphocyte functions, we hypothesized that RANKL production might also be subject to modulation by oxidized lipids. Here, we show that short term exposure of both unstimulated and activated human T lymphocytes to minimally oxidized low density lipoprotein (LDL), but not native LDL, significantly enhances RANKL production and promotes expression of the lectin-like oxidized LDL receptor-1 (LOX-1). The effect, which is also observed with 8-iso-Prostaglandin E2, an inflammatory isoprostane produced by lipid peroxidation, is mediated via the NFκB pathway, and involves increased RANKL mRNA expression. The link between oxidized lipids and T lymphocytes is further reinforced by analysis of hyperlipidemic mice, in which bone loss is associated with increased RANKL mRNA in T lymphocytes and elevated RANKL serum levels. Our results suggest a novel pathway by which T lymphocytes contribute to bone changes, namely, via oxidized lipid enhancement of RANKL production. These findings may help elucidate clinical associations between cardiovascular disease and decreased bone mass, and may also lead to new immune-based approaches to osteoporosis.
Introduction
Osteoporosis and osteopenia are asymptomatic systemic pathologies that are characterized by decreased bone mass and diminished skeletal integrity. Reduced bone mass is associated with greater risk of fracture, as well as increased morbidity and mortality and elevated health care expenditures [1] and [2]. The dynamic process of bone remodeling had heretofore been assumed to mainly involve osteoblasts, bone forming cells that secrete organic matrix molecules, and bone-resorbing osteoclasts, which are derived from hematopoietic precursors. However, it is becoming increasingly evident that the immune system also plays a significant role in bone homeostasis [3]. Indeed, the term "osteoimmunology" was coined to reflect the intricate bidirectional communication between the immune and skeletal systems [4].
A central component of the interaction between the immune and skeletal systems is the tumor necrosis factor (TNF) receptor family molecule, receptor activator of NFκB ligand (RANKL). This protein (also known as TNF-related activation cytokine, TRANCE) was actually first identified as a T lymphocyte surface marker that had regulatory effects on immune cell function [5]; only later was it shown to also be essential for the differentiation, activation, and survival of osteoclasts [6], [7] and [8]. RANKL, which is now known to be secreted by activated T lymphocytes, has been studied extensively in the context of bone loss associated with rheumatoid arthritis [9] and [10], periodontal disease [11] and [12], and osteoporosis [3], where it has been shown to bind to RANK on osteoclasts, and induce these bone-resorbing cells to mature and become active. The regulation of T lymphocyte RANKL production in response to physiologic stimuli that are distinct from those that mediate activation via the antigen receptor has not been studied.
The notion that products of lipid and lipoprotein oxidation may contribute to the pathophysiology of osteoporosis is suggested by a variety of studies [13], [14] and [15]. Epidemiological analyses have repeatedly shown associations between osteoporosis and hyperlipidemia [16], [17], [18], [19], [20], [21] and [22], and patients with lower bone density and osteoporosis have higher lipid levels, more severe coronary atherosclerosis and increased risk of stroke [18], [20], [23], [24] and [25]. Conversely, lipid-lowering treatments are associated with both reduced coronary vascular calcification [26] and fewer osteoporotic fractures [27], [28], [29] and [30]. In vitro studies demonstrate that minimally oxidized LDL (MM-LDL) inhibits the differentiation of osteoblasts [31] and can induce differentiation of osteoclasts [32]. Within the immune system, oxidized LDL is an inducer of apoptosis in T lymphocytes [33], and mildly oxidized LDL decreases early production of IL-2 by T lymphocytes [34]. In addition, dendritic cell function is inhibited in a mouse model of high-fat diet-induced dyslipidemia [35].
Since bone development and repair require adequate vascularization [36], it is likely that both circulating lipoproteins and immune cells are in close contact with cortical and trabecular bone. Therefore, in the present study, we sought to examine whether oxidized lipids, and particularly, MM-LDL, which is highly inflammatory, might have a direct effect on T lymphocyte RANKL production. Our results show that exposure of both ex vivo, unmanipulated human T lymphocytes, as well as in vitro-activated T lymphocytes to MM-LDL, results in enhanced RANKL secretion, involving the NFκB pathway and increased RANKL transcripts. Oxidized lipids also induced expression of the lectin-like oxidized LDL receptor-1 (LOX-1) on T lymphocytes. Complementary in vivo data from a mouse model of high-fat diet-induced osteopenia show that these mice have elevated serum levels of RANKL as well as increased T lymphocyte RANKL mRNA. These observations support a role for oxidized lipids in immune-mediated bone loss, and provide a possible mechanistic link for the well-documented association between dyslipidemia and osteoporosis.
Discussion
The present study provides the first demonstration that oxidized lipids can induce human T lymphocytes to secrete RANKL, a cytokine that is a key mediator of osteoclast differentiation and bone loss. We show that exposure of human T lymphocytes to either the lipoprotein oxidation product, MM-LDL, or to iso-PGE2, a by-product of the free radical-catalyzed peroxidation of essential fatty acids, significantly increases RANKL production. The effect is observed in unstimulated T lymphocytes tested immediately ex vivo, as well as in T lymphocytes stimulated via activatory antibodies. The MM-LDL induction of RANKL protein is preceded by upregulation of RANKL mRNA, and the effect on the unstimulated T lymphocytes is mediated through the NFκB pathway. Additionally, T lymphocytes exposed to oxidized lipids had higher RANKL:OPG ratios, which might further disrupt bone homeostasis in vivo. Our study also provides the first evidence that LOX-1, previously documented on endothelial cells and macrophages, is also expressed on primary T lymphocytes. Consistent with our in vitro observations on human T lymphocytes, splenic T lymphocytes from hyperlipidemic mice, which show both bone loss and increased levels of oxidized lipids [13] F. Parhami, Possible role of oxidized lipids in osteoporosis: could hyperlipidemia be a risk factor?, Prostaglandins Leukot Essent Fatty Acids 68 (2003), pp. 373-378. Abstract | Article | PDF (108 K) | View Record in Scopus | Cited By in Scopus (18)[13] and [57], also express significantly greater RANKL mRNA. Thus T lymphocytes may be one of the sources of the significantly higher serum levels of RANKL protein in these mice. The results of our study provide a novel pathway by which T lymphocytes may contribute to bone loss, and suggest that the well-established association between cardiovascular disease and bone loss [13], [16], [58] and [59] may involve T lymphocytes, along with other known sources of RANKL.
Our results expand upon the growing repertoire of diverse biological effects mediated by oxidized lipids on cells of the immune system. For example, human peripheral blood T lymphocytes are strongly inhibited in anti-CD3/CD28-induced proliferation and de novo synthesis of activation markers by certain concentrations of Ox-PAPC, an oxidized phospholipid [48], consistent with the proposed link between sterol metabolism and T cell proliferative responses to antigens [60]. Oxidized lipids have also been shown to negatively regulate dendritic cell maturation. Human dendritic cells that are pretreated with Ox-PAPC are inhibited in LPS-induced upregulation of a variety of surface markers, including the CD40 and CD80 costimulatory molecules, the ICAM-1 cell adhesion marker, and MHC Class I and II transplantation antigens [50]. Finally, in macrophages, MM-LDL is able to offset the apoptosis induction by more extensively oxidized LDL [61]. Thus, oxidized lipids have diverse and important regulatory functions within both the innate and adaptive immune systems.
LOX-1, the specific receptor for oxidized forms of lipids [62] has been studied in a variety of non-immune cell types, such as cells within the placenta [63], chondrocytes, [64] breast cancer cells [65] and endothelial cells, in which it not only mediates uptake of Ox-LDL, but also functions as a scavenger receptor that interacts with a variety of distinct ligands such as platelets, apoptotic cells, heat shock proteins, and phosphatidylserine [51], [54] and [66]. To our knowledge, our study is the first to demonstrate that LOX-1 is induced on primary T lymphocytes. Interestingly, C-reactive protein (CRP), an acute phase serum marker that is a strong predictor of cardiovascular disease, hypertension and diabetes [67] and [68] also binds to LOX-1. Ongoing studies in our laboratory are, therefore, examining the potential involvement of CRP in the MM-LDL induction of T lymphocyte-mediated bone loss.
Our study provides another example of the interplay of immune cells and oxidized lipids in a disease that has major implications for human health. This interaction has already been documented for atherosclerosis, in which one of the initiating events is the uptake of oxidized lipids by macrophages, leading to the formation of the foam cells that are involved in the actual plaque formation [69], [70], [71] and [72]. Oxidized lipids may also stimulate autoreactive T lymphocytes, which could further contribute to atherosclerosis. Indeed, adoptive transfer of Ox-LDL-reactive CD4 T lymphocytes into mice that are genetically engineered to develop atherosclerosis leads to accelerated lesion progression [73]. Moreover, human CD8 T cells can mediate Ox-LDL-specific cytotoxicity, thus contributing to the inflammatory process associated with atherosclerosis [74]. A role for oxidized phospholipids has recently been documented in human leprosy, where host-derived oxidized phospholipids accumulate in macrophages within lepromatous lesions, a process that is strikingly similar to observations in atherosclerotic lesions [75]. Finally, recent research has also suggested an association between lipid levels and both telomerase activity and telomere length in PBMC [76] and [77], findings which have important implications for immunosenescence. Thus, immune-mediated pathogenic changes in a variety of diseases have been documented to be modulated by oxidized lipids. Our ongoing in vitro studies on the effects of long-term exposure of T lymphocytes to oxidized lipids may identify additional effects that relate to age-related pathologies in addition to bone loss.
It has been well-established that chronic immune activation plays a key role in bone homeostasis. Indeed, skeletal changes are observed in a variety of clinical situations involving chronic, long-term immune activation. For example, reduced bone mass is being increasingly reported in HIV/AIDS, even in the absence of anti-retroviral drugs [78]. RANKL production by activated T lymphocytes has also been shown to play a central role in inflammatory bone loss, particularly in rheumatoid arthritis. The current study provides the first demonstration that not only activated, but also resting, unstimulated T lymphocytes are potential sources of RANKL, if they are exposed to oxidized lipids. In summary, our results underscore the interaction between T lymphocytes and oxidized lipids in osteoporosis and osteopenia, and provide a possible pathway for the documented improved bone mass seen in patients who are treated with lipid-lowering medications [26] and [28].
Results
RANKL production is induced in human T lymphocytes by oxidized lipids
Consistent with previous reports [44], we observed that T lymphocytes stimulated with CD2/CD3/CD28 antibodies produce high levels of RANKL, which can be detected by ELISA (data not shown). To address the potential effect of oxidized lipids on T lymphocyte RANKL production, we selected MM-LDL for these experiments since it is known to be highly inflammatory, yet does not induce the cytotoxicity associated with highly oxidized LDL. Preliminary titration experiments were performed to identify the optimum concentration of MM-LDL required to induce maximum RANKL production without compromising cell viability. Highly purified human T lymphocytes were exposed to various concentrations of MM-LDL (0, 1, 10, 25, 50, 100 µg/ml) for 72 h. As shown in Figure 1A, MM-LDL concentrations up to 25 µg/ml had no effect on cell viability, whereas the higher concentrations were toxic, as determined by trypan blue dye exclusion. Flow cytometric Annexin V and PI staining confirmed that exposure of T lymphocytes to 25 µg/ml of MM-LDL did not cause significant cell death (data not shown). Thus, although 50 µg/ml MM-LDL induced the highest level of RANKL production, due to the dramatic loss in cell viability at this concentration, all subsequent experiments were performed using 25 µg/ml (Fig. 1B). Nevertheless, to further control for any minor differences in cell viability over the 72-hour incubation period, RANKL production by T lymphocytes was also normalized based on the production per million viable cells; these values were similar to those displayed in Figures 1C, D, E, F and 2A, B.
The first set of experiments evaluated whether MM-LDL had an additive effect on the already robust levels of activation-induced T lymphocyte RANKL production. We observed that the concentration of RANKL in the culture supernatants of purified T lymphocytes stimulated with CD2/CD3/CD28 antibodies was significantly increased in the presence of MM-LDL, as compared to buffer or native LDL (nLDL). Figure 1C shows representative ELISA data for one donor, and in Figure 1D, the results of experiments on purified T lymphocytes from 18 individual donors are presented. Unexpectedly, even in the absence of an activation stimulus, exposure of T lymphocytes to MM-LDL resulted in a significant increase in RANKL production (Fig. 1E). Indeed, this pattern was seen in T lymphocytes from all 15 healthy individuals tested, with fold-increases (over buffer alone) ranging from 4 to 55, and a mean fold-increase of 16 (Fig. 1F). The effect of MM-LDL on unstimulated T lymphocyte RANKL production was significantly greater than that of nLDL, which had only a modest effect (Fig. 1F). Flow cytometry evaluation of the CD38, CD25 and HLA-DR activation markers confirmed that the RANKL production by unstimulated T lymphocytes was not due to possible MM-LDL induced activation (data not shown). QT-PCR experiments showed that the increased RANKL protein induced in unstimulated T lymphocytes exposed to MM-LDL was associated with a significant increase in RANKL mRNA (Fig. 1G). Osteoprotegerin (OPG) is a natural decoy receptor that blocks RANKL from binding to its receptor (RANK) and the ratio of RANKL to OPG is considered a key parameter in regulating bone metabolism. Unstimulated T lymphocytes exposed to MM-LDL had lower OPG expression compared to nLDL (Fig. 1G), and the RANKL: OPG ratio for nLDL and MM-LDL is 0.9 and 3.4, respectively. To determine whether MM-LDL exposure induced unstimulated T lymphocytes to produce osteoclastogenic factors in addition to RANKL, ELISA assays were performed. These assays, which detect concentrations as low as 0.7 pg/ml, 1.6 pg/ml, and 4.6 pg/ml of IL-6, TNFα, and TGFß, respectively, did not show any increases in these cytokines (data not shown).
In parallel with our in vitro experiments on human T lymphocytes, we evaluated an in vivo model of bone loss induced in C57BL/6 mice that become hyperlipidemic when treated with a high-fat diet [41]. Consistent with our earlier studies [41], pQCT analysis of femoral bones from high-fat fed mice showed a significant reduction in bone mineral content compared to their chow-fed counterparts (Table 1). Importantly, T lymphocytes from these mice, tested immediately ex vivo, in the absence of any stimulation, expressed RANKL mRNA that was significantly greater than that of T lymphocytes from the chow-fed mice (Fig. 1H). The hyperlipidemic mice also had significant increases in serum levels of RANKL protein (Fig. 1I). Overall, the in vitro data on human T lymphocytes, and the murine in vivo model of hyperlipidemia-induced bone loss indicate that exposure to oxidized lipids enhances T lymphocyte RANKL production.
iso-PGE2 also induces RANKL production by unstimulated human T lymphocytes
The prostaglandin-like isoprostane, 8-iso-Prostaglandin E2 (iso-PGE2), is produced in vivo as one of the by-products of free radical-catalyzed lipid peroxidation, and may contribute to oxidative injury [45]. Previous studies have shown that oxidized lipids, including iso-PGE2, inhibit differentiation of preosteoblasts [31] F. Parhami, A.D. Morrow, J. Balucan, N. Leitinger, A.D. Watson, Y. Tintut, J.A. Berliner and L.L. Demer, Lipid oxidation products have opposite effects on calcifying vascular cell and bone cell differentiation. A possible explanation for the paradox of arterial calcification in osteoporotic patients, Arterioscler. Thromb. Vasc. Biol. 17 (1997), pp. 680-687. View Record in Scopus | Cited By in Scopus (270)[31], [32], [46] and [47]. Titration experiments on unstimulated T lymphocytes showed that the maximum RANKL production was induced in the presence of 25 µM iso-PGE2 (Fig. 2A). We found that unstimulated T lymphocytes exposed to iso-PGE2 produced a mean increase in RANKL protein that was 4-fold greater than that of control cultures exposed to the DMSO diluent (Fig. 2B). QT-PCR experiments showed that the increased RANKL protein induced in unstimulated T lymphocytes exposed to iso-PGE2 was preceded by increased RANKL mRNA (Fig. 2C). We also found that T lymphocytes exposed to iso-PGE2 had lower OPG expression as compared to DMSO, with RANKL:OPG ratios of 0.9 and 5.3 for DMSO and iso-PGE2, respectively. Ox-PAPC (oxidized 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine), a biologically active component of MM-LDL, which is known to have pleiotropic effects on human endothelial cells [46] and also affects T lymphocyte activation [48], was found to be toxic to unstimulated human T lymphocytes, even at concentrations as low as 0.5 µg/ml (data not shown).
MM-LDL induction of T lymphocyte RANKL requires NFκB signaling
To elucidate the mechanism involved in the oxidized lipid-induced RANKL production in T lymphocytes, we tested a panel of pathway inhibitors, using concentrations that did not affect cell viability. We first investigated the NFκB pathway, based on previous reports showing that this pathway is central to the maturation and activation of osteoclast precursor cells induced by RANK/RANKL binding [44]. Furthermore, the biological activity of MM-LDL and oxidized lipids in several other cell types is mediated, at least in part, through the NFκB pathway [49]. Two different NFκB inhibitors were used, one that blocks the translocation of the active NFκB complex from the cytoplasm into the nucleus (inhibitor 1), and one that prevents the phosphorylation of IκBα (inhibitor 2). We found that the MM-LDL-induced RANKL production by the stimulated T lymphocytes was only modestly reduced when the NFκB pathway was inhibited. (Fig. 3A). By contrast, in the unstimulated T lymphocytes, RANKL production induced by MM-LDL was nearly completely abolished in the presence of the NFκB inhibitors (Fig. 3B). The NFκB pathway role in this effect was further confirmed using an assay that measures the presence of the NFκB p65 subunit in the nucleus, a downstream effect of NFκB activation. A one-hour incubation of unstimulated T lymphocytes with MM-LDL resulted in a 2-fold increase in nuclear p65; this activity decreased after 2 h (Fig. 3C). No inhibition of the MM-LDL induction of RANKL production by unstimulated T lymphocytes was observed in the presence of specific MAPK (10 µM), PKA (5 µM) and PKC (1 µM) pathway inhibitors (data not shown). Thus, our data indicate that unstimulated T lymphocytes exposed to MM-LDL upregulate RANKL message and protein via an NFκB-mediated pathway. The very modest reduction in RANKL seen in the stimulated T lymphocytes exposed to MM-LDL (Fig. 3A) suggests that RANKL induction in activated T lymphocytes may be mediated by both NFκB-dependent and -independent pathways. Other reports on oxidized lipid effects in several cell types suggest varying degrees of NFκB pathway involvement in response to oxidized lipids, ranging from total absence of NFκB signaling [46] and [47] to inhibitory effects on the NFκB pathway [35] A.T. Shamshiev, F. Ampenberger, B. Ernst, L. Rohrer, B.J. Marsland and M. Kopf, Dyslipidemia inhibits Toll-like receptor-induced activation of CD8alpha-negative dendritic cells and protective Th1 type immunity, J. Exp. Med. 204 (2007), pp. 441-452. View Record in Scopus | Cited By in Scopus (9)[35] and [50], depending on cell type, function being assessed and the type of oxidized lipids tested.
Oxidized lipids induce T lymphocyte LOX-1 expression
The lectin-like oxidized LDL receptor-1 (LOX-1) has been identified as the primary Ox-LDL receptor on endothelial cells [51] and is associated with cardiovascular disease [52] and [53]. Macrophages also express LOX-1 when exposed to TNF-α [54]. A recent report documented LOX-1 mRNA in the Jurkat T cell tumor line following exposure to a component of oxidized lipids [55], suggesting that normal T lymphocytes, which infiltrate and accumulate in the vascular wall during the development of atherosclerosis [56] G.K. Hansson, P. Libby, U. Schonbeck and Z.Q. Yan, Innate and adaptive immunity in the pathogenesis of atherosclerosis, Circ. Res. 91 (2002), pp. 281-291. View Record in Scopus | Cited By in Scopus (390)[56], and are therefore exposed to Ox-LDL in vivo might also express LOX-1. Purified T lymphocytes were exposed to 25 µg/ml MM-LDL, 25 µg/ml nLDL, 25 µM iso-PGE2 or control buffers for 72 h and then analyzed by flow cytometry. Figure 4A shows a flow cytometry histogram for a representative donor, and in Figure 4B, the results of experiments on purified T lymphocytes from 9 unstimulated and 10 stimulated samples. Our data show that the percentage of LOX-1 positive T lymphocytes treated with oxidized lipids ranged from 1 to 10% for unstimulated and 10-39% for activated cells (Fig. 4B), and both CD4 and CD8 T lymphocytes were found to express LOX-1(data not shown). The effect of oxidized lipids on LOX-1 expression was significantly higher than that of nLDL on both unstimulated and PHA-activated T lymphocytes. These data show that unstimulated T lymphocytes exposed to either MM-LDL or iso-PGE2 had fold-changes in surface LOX-1 expression (over control buffers) of 6.1 and 3.5, respectively; the fold-changes for the activated T lymphocytes were 3.0 and 2.0, respectively. QT-PCR experiments showed that increased LOX-1 expression on cell surface of T lymphocytes exposed to oxidized lipids was associated with increased LOX-1 mRNA (Fig. 4C).
Materials and methods
Cell isolation and culture
Human peripheral blood mononuclear cells (PBMCs) from healthy donors with normal lipid levels, as documented by the UCLA Clinical Labs, were isolated by density-gradient centrifugation on Ficoll-Hypaque (Cellgro). T lymphocytes were purified by immunomagnetic depletion using a mixture of biotinylated mAbs against CD14, CD16, CD19, CD56, CD36, CD123, and CD235a, which were subsequently labeled with anti-biotin microbeads (Miltenyi Biotec). Purity of T lymphocytes (> 98%) was confirmed by flow cytometry (Becton Dickson) using anti-CD3 antibody (BD Pharmingen). Cell viability following purification was consistently > 90%, as assessed by trypan blue exclusion. Cells were plated at a concentration of 1 x 106/ml in AIM-V serum-free medium (Gibco) for cell culture experiments. For experiments testing activated cells, the T lymphocytes were stimulated with either CD2/CD3/CD28-antibody-coated beads (Miltenyi Biotec) at a bead:cell ratio of 1:1 or 6 µg/ml PHA (Sigma).
Lipoprotein preparation and oxidation
Human LDL was isolated by density-gradient centrifugation of serum, and stored in phosphate-buffered 0.15 M NaCl containing 0.01% EDTA [37]. Minimally oxidized LDL was prepared by iron oxidation of human LDL, as described in Parhami et al. [31]. Minimal oxidation of LDL resulted in a 3- to 4-fold increase in conjugated dienes. The lipoproteins were tested pre- and post-oxidation for lipopolysaccharide levels and found to have < 30 pg of lipopolysaccharide/ml of medium. In some experiments, components of MM-LDL were tested, including 8-iso-Prostaglandin E2 (iso-PGE2; Cayman Chemical) and oxidized 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine (Ox-PAPC), which was a generous gift of Dr. Judy Berliner, UCLA. The concentrations of lipoproteins used in this study are reported in micrograms of protein.
Cytokine measurement
Supernatants from cultured cells were harvested after 72 h of incubation with 25 µg/ml nLDL, MM-LDL, 25 µM iso-PGE2 or control buffer, centrifuged, and immediately frozen at - 80 °C until further analysis. All samples were thawed immediately prior to ELISA evaluation. The following ELISA kits were used: RANKL, (Peprotech), IFN y (Biotrack ELISA System, Amersham), IL-6, TGF-ß and TNFα (Quantikine, R and D Systems). All measurements were performed in triplicate wells, and in accordance to the manufacturer's instructions.
Flow cytometry
Cell activation status and viability were assessed by flow cytometry. Cells were harvested after 72 h of incubation with 25 µg/ml nLDL, MM-LDL or buffer control, centrifuged and washed twice with 1x PBS, then resuspended in 1x binding buffer (BD Biosciences) prior to the staining. Briefly, cells were incubated with Annexin V-FITC, propidium iodide (PI), CD38 PerCp-Cy5.5, CD25 APC-Cy7, HLA-DR APC, CD8 PE-Cy7 (BD Biosciences) and CD3 Pacific Blue (Invitrogen) for 15 min at room temperature in the dark, washed and resuspended in 1x binding buffer. The 7-color staining flow cytometry data was acquired immediately by BD LSRII and FACS Diva software (BD Biosciences). Data analysis was performed using FlowJo (Tree Star). Cells that were negative for Annexin V and PI were considered as viable; apoptotic cells (Annexin V+) and necrotic cells (both Annexin V+/PI+ or PI+ alone) were detected and quantified as a percentage of the entire population [38]. Data from 4 independent experiments, each performed on triplicate samples, were pooled to determine the mean cell viability. For LOX-1 measurement, cells were harvested after 72 h of incubation with 25 µg/ml nLDL, MM-LDL, 25 µM iso-PGE2, or control buffer, centrifuged and washed twice with 1x PBS, then resuspended with staining buffer (BD Biosciences). Cells were incubated with biotinylated LOX-1 (Hycult Biotechnology), CD8 PerCp, and CD3 APC (BD Biosciences) for 30 min at 4 °C in the dark, washed and resuspended in staining buffer for secondary staining for 30 min at 4 °C in the dark. Cell acquisition and data analysis were performed as described above.
Mice and diets
Male C57Bl/6 (atherosclerosis-susceptible strain) mice (Jackson Laboratory) were placed on either a control chow diet (National Institute of Health [NIH]-31 Mouse/Rat Diet 7013 containing 6% fat) or high-fat (atherogenic) diet (Teklad TD90221; Harlan Tekland; containing 1.25% cholesterol, 15.8% fat, and 0.5% cholate) starting at 1 month of age. This diet causes significant hypercholesterolemia [39] and [40] and osteopenia [41] in C57Bl/6 mice. Spleen and serum were collected from control and high-fat diet fed animals at 11 months of age. T lymphocytes were isolated from splenocytes by immunomagnetic negative selection, using a mixture of mAbs of biotinylated CD14, CD16, CD19, CD56, CD36, CD123, CD235a and subsequently labeled with anti-biotin microbeads (Miltenyi Biotec). Purity of T lymphocytes (> 98%) was confirmed by flow cytometry (Becton Dickson) using anti-CD3 antibody (BD Pharmingen).
Quantitative computed tomographic scanning
Femurs were carefully cleaned of soft tissue and fixed in 95% ethanol. Peripheral quantitative computed tomographic (pQCT) scans were performed on the left femur from each mouse. Scanning was done with a Stratec XCT-Research M (Norland Medical Systems) and associated software (version 5.4; Stratec Medizintechnik), and Bone Mineral Content (BMC) analysis was performed as previously described [42]. The mean of 3 evenly-spaced slices located in the mid-diaphysis was selected for data analysis.
Pathway inhibitors
The following pathway inhibitors were used: Akt inhibitors (124005 or 124009 - Calbiochem; both at 25 µM), MAPK inhibitor (PD98059 - Calbiochem at 10 µM), NFκB inhibitors (sc3060 - Santa Cruz Biotechnology at 75 µg/ml (inhibitor 1) or Bay 11-7082 - BioMol at 2 µM (inhibitor 2)), PKA inhibitor (H89 - Calbiochem at 5 µM), and PKC inhibitor (RO-31-7549 - Calbiochem at 1 µM). All inhibitors were dissolved in DMSO, according to the manufacturer's instruction, except for inhibitor 1 (sc-3060), which was dissolved in 1x PBS supplemented with 0.2% BSA and 0.1% NaN3. Prior to treatment with oxidized lipids or control buffer, T lymphocytes, at a concentration of 1 x 106/ml, were pre-incubated with inhibitors or appropriate vehicle for 2 h at 37 °C.
NFκB activity assay
Purified T lymphocytes were incubated with 25 µg/ml MM-LDL for 1 h or up to 2 h, then harvested, and the pellet washed with ice-cold PBS/Phosphatase inhibitors. Nuclear extraction and analysis were performed according to the manufacturer's instructions (Active Motif). The nuclear fraction was analyzed using a TransAM NFκB family transcription factor assay kit. Briefly, in a 96-well plate, the active form of NFκB in the nuclear extract binds specifically to the oligonucleotide containing the NFκB consensus binding site (GGGACTTTCC) that has been immobilized on the plate. To monitor the specificity of the assay, the wild-type consensus oligonucleotide competitor for NFκB binding is added to the well prior to addition of cell extract. Activated NFκB was detected by the addition of primary antibody for the p65 subunit, and measurement was achieved with a HRP-conjugated secondary antibody, providing a colorimetric readout at 450 nm with a reference wavelength of 655 nm.
Quantitative real-time PCR (QT-PCR) for RANKL expression
Purified T lymphocytes were incubated with 25 µg/ml of nLDL or MM-LDL, or 25 µM iso-PGE2 for 24 h. Total RNA was extracted using RNeasy Mini Kit (Qiagen), and RNA concentrations were determined using the Quant-iT Ribogreen RNA Assay Kit (Molecular Probes). Template cDNAs were synthesized with the iScript cDNA synthesis kit (Bio-Rad) using 500 ng of RNA. The QT-PCR assays were performed using the iQ SYBR Green SuperMix and IQCycler (Bio-Rad). As an internal control, QT-PCR for the housekeeping gene, GAPDH, was performed. The sequences of the primers were designed with the aid from the Beacon software. hRANKL - 3'-TATCGTTGGATCACAGCACATCAGAG; 5'-GAGGACAGACTCACTTTATGGGAACC. hOPG - 3'-TGTGAGGAGGCATTCTTCAGGTTTG; 5'-TCTCTACACTCTCTGCGTTTACTTTGG. hLOX-1 - 3'-TGGGAAAAGAGCCAAGAGAA; 5'-TAAGTGGGGCATCAAAGGAG. hGAPDH - 3'-CCTCAAGATCATCAGCAATGCCTCCT; 5'-GGTCATGAGTCCTTCCACGATACCAA. mRANKL - 3'-GCCTCCCGCTCCATGTTCC; 5'-TGAGTGCTGTCTTCTGATATTCTGTTAG. mGAPDH - 3'-ATTGTCAGCAATGCATCCTG; 5'-ATGGACTGTGGTCATGAGCC. Samples were run in triplicate in a 96-well plate using the settings of 95 °C for 15 s, 61 °C for 30 s and 72 °C for 30 s (single fluorescence measurement).
Statistical analysis
Data in the graphs indicate the mean ± S calculated from independent experiments. The Wilcoxon rank sum test, a non-parametric test that is powerful in analyzing small sample sizes [43], was used to compare groups. Statistical significance was defined as p ≤ 0.05.
References
[1] R. Burge, B. Dawson-Hughes, D.H. Solomon, J.B. Wong, A. King and A. Tosteson, Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025, J. Bone Miner. Res. 22 (2007), pp. 465-475.
[2] J.A. Kanis, Diagnosis of osteoporosis and assessment of fracture risk, Lancet 359 (2002), pp. 1929-1936.
[3] M.C. Walsh, N. Kim, Y. Kadono, J. Rho, S.Y. Lee, J. Lorenzo and Y. Choi, Osteoimmunology: interplay between the immune system and bone metabolism, Annu. Rev. Immunol. 24 (2006), pp. 33-63.
[4] J.R. Arron and Y. Choi, Bone versus immune system, Nature 408 (2000), pp. 535-536.
[5] B.R. Wong, J. Rho, J. Arron, E. Robinson, J. Orlinick, M. Chao, S. Kalachikov, E. Cayani, F.S. Bartlett, W.N. Frankel, S.Y. Lee and Y. Choi, TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells, J. Biol. Chem. 272 (1997), pp. 25190-25194.
[6] D.L. Lacey, E. Timms, H.L. Tan, M.J. Kelley, C.R. Dunstan, T. Burgess, R. Elliott, A. Colombero, G. Elliott, S. Scully, H. Hsu, J. Sullivan, N. Hawkins, E. Davy, C. Capparelli, A. Eli, Y.X. Qian, S. Kaufman, I. Sarosi, V. Shalhoub, G. Senaldi, J. Guo, J. Delaney and W.J. Boyle, Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation, Cell 93 (1998), pp. 165-176.
[7] B.R. Wong, R. Josien and Y. Choi, TRANCE is a TNF family member that regulates dendritic cell and osteoclast function, J. Leukoc. Biol. 65 (1999), pp. 715-724.
[8] H. Yasuda, N. Shima, N. Nakagawa, K. Yamaguchi, M. Kinosaki, S. Mochizuki, A. Tomoyasu, K. Yano, M. Goto, A. Murakami, E. Tsuda, T. Morinaga, K. Higashio, N. Udagawa, N. Takahashi and T. Suda, Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL, Proc. Natl. Acad. Sci. U. S. A. 95 (1998), pp. 3597-3602.
[9] Y.Y. Kong, U. Feige, I. Sarosi, B. Bolon, A. Tafuri, S. Morony, C. Capparelli, J. Li, R. Elliott, S. McCabe, T. Wong, G. Campagnuolo, E. Moran, E.R. Bogoch, G. Van, L.T. Nguyen, P.S. Ohashi, D.L. Lacey, E. Fish, W.J. Boyle and J.M. Penninger, Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand, Nature 402 (1999), pp. 304-309.
[10] A. Vanderborght, L. Linsen, M. Thewissen, P. Geusens, J. Raus and P. Stinissen, Osteoprotegerin and receptor activator of nuclear factor-kappaB ligand mRNA expression in patients with rheumatoid arthritis and healthy controls, J. Rheumatol. 31 (2004), pp. 1483-1490.
[11] D. Liu, J. Xu, L. Figliomeni, L. Huang, N. Pavlos, M. Rogers, A. Tan, P. Price and M. Zheng, Expression of RANKL and OPG mRNA in periodontal disease: possible involvement in bone destruction, Int. J. Mol. Med. 11 (2003), pp. 17-21.
[12] P.J. Baker, L. Howe, J. Garneau and D.C. Roopenian, T cell knockout mice have diminished alveolar bone loss after oral infection with Porphyromonas gingivalis, FEMS Immunol. Med. Microbiol. 34 (2002), pp. 45-50.
[13] F. Parhami, Possible role of oxidized lipids in osteoporosis: could hyperlipidemia be a risk factor?, Prostaglandins Leukot Essent Fatty Acids 68 (2003), pp. 373-378.
[14] N.M. Rajamannan, Low-density lipoprotein and aortic stenosis, Heart 94 (2008), pp. 1111-1112.
[15] N.M. Rajamannan, M. Subramaniam and D. Rickard, Human aortic valve calcification is associated with osteoblast phenotype, Circulation 107 (2003), pp. 2181-2184.
[16] L.M. Banks, B. Lees, J.E. MacSweeney and J.C. Stevenson, Effect of degenerative spinal and aortic calcification on bone density measurements in post-menopausal women: links between osteoporosis and cardiovascular disease?, Eur. J. Clin. Invest. 24 (1994), pp. 813-817.
[17] L.B. Tanko, Y.Z. Bagger and C. Christiansen, Low bone mineral density in the hip as a marker of advanced atherosclerosis in elderly women, Calcif. Tissue Int. 73 (2003), pp. 15-20.
[18] P.D. Broulik and J. Kapitola, Interrelations between body weight, cigarette smoking and spine mineral density in osteoporotic Czech women, Endocr. Regul. 27 (1993), pp. 57-60. View Record in Scopus | Cited By in Scopus (23)
[19] K.G. Jie, M.L. Bots, C. Vermeer, J.C. Witteman and D.E. Grobbee, Vitamin K status and bone mass in women with and without aortic atherosclerosis: a population-based study, Calcif. Tissue Int. 59 (1996), pp. 352-356.
[20] M. Laroche, J.M. Pouilles, C. Ribot, P. Bendayan, J. Bernard, H. Boccalon and B. Mazieres, Comparison of the bone mineral content of the lower limbs in men with ischaemic atherosclerotic disease, Clin. Rheumatol. 13 (1994), pp. 611-614.
[21] Y. Ouchi, M. Akishita, A.C. de Souza, T. Nakamura and H. Orimo, Age-related loss of bone mass and aortic/aortic valve calcification-reevaluation of recommended dietary allowance of calcium in the elderly, Ann. N.Y. Acad. Sci. 676 (1993), pp. 297-307.
[22] Y. Tintut, S. Morony and L.L. Demer, Hyperlipidemia promotes osteoclastic potential of bone marrow cells ex vivo, Arterioscler Thromb. Vasc. Biol. 24 (2004), pp. e6-10.
[23] E.I. Barengolts, M. Berman, S.C. Kukreja, T. Kouznetsova, C. Lin and E.V. Chomka, Osteoporosis and coronary atherosclerosis in asymptomatic postmenopausal women, Calcif. Tissue Int. 62 (1998), pp. 209-213. View Record in Scopus | Cited By in Scopus (137)
[24] W.S. Browner, D.G. Seeley, T.M. Vogt and S.R. Cummings, Non-trauma mortality in elderly women with low bone mineral density. Study of Osteoporotic Fractures Research Group, Lancet 338 (1991), pp. 355-358.
[25] O. Uyama, Y. Yoshimoto, Y. Yamamoto and A. Kawai, Bone changes and carotid atherosclerosis in postmenopausal women, Stroke 28 (1997), pp. 1730-1732. View Record in Scopus | Cited By in Scopus (92)
[26] C.J. Edwards, D.J. Hart and T.D. Spector, Oral statins and increased bone-mineral density in postmenopausal women, Lancet 355 (2000), pp. 2218-2219.
[27] T.Q. Callister, P. Raggi, B. Cooil, N.J. Lippolis and D.J. Russo, Effect of HMG-CoA reductase inhibitors on coronary artery disease as assessed by electron-beam computed tomography, N. Engl. J. Med. 339 (1998), pp. 1972-1978.
[28] C.R. Meier, R.G. Schlienger, M.E. Kraenzlin, B. Schlegel and H. Jick, Statins and fracture risk, JAMA 286 (2001), pp. 669-670.
[29] C.R. Meier, R.G. Schlienger, M.E. Kraenzlin, B. Schlegel and H. Jick, HMG-CoA reductase inhibitors and the risk of fractures, JAMA 283 (2000), pp. 3205-3210.
[30] R.G. Schlienger, M.E. Kraenzlin, S.S. Jick and C.R. Meier, Use of beta-blockers and risk of fractures, JAMA 292 (2004), pp. 1326-1332.
[31] F. Parhami, A.D. Morrow, J. Balucan, N. Leitinger, A.D. Watson, Y. Tintut, J.A. Berliner and L.L. Demer, Lipid oxidation products have opposite effects on calcifying vascular cell and bone cell differentiation. A possible explanation for the paradox of arterial calcification in osteoporotic patients, Arterioscler. Thromb. Vasc. Biol. 17 (1997), pp. 680-687.
[32] Y. Tintut, F. Parhami, A. Tsingotjidou, S. Tetradis, M. Territo and L.L. Demer, 8-Isoprostaglandin E2 enhances receptor-activated NFkappa B ligand (RANKL)-dependent osteoclastic potential of marrow hematopoietic precursors via the cAMP pathway, J. Biol. Chem. 277 (2002), pp. 14221-14226.
[33] M. Bustamante, F. Diaz, M. Munoz, H.J. Gross, C.I. Rivas, A. Llancaqueo, L. Nunez, L. Campos, L. Kirsten, J. Grandon, M. Gonzalez, V. Barra, J.C. Vera and M.G. Bachem, Oxidized low density lipoproteins induce apoptosis in human lymphocytes: involvement of mitogen-activated protein kinases, Cell Mol. Biol. (Noisy-le-grand) 53 Suppl (2007), pp. OL954-64.
[34] S. Caspar-Bauguil, J. Tkaczuk, M.J. Haure, M. Durand, J. Alcouffe, M. Thomsen, R. Salvayre and H. Benoist, Mildly oxidized low-density lipoproteins decrease early production of interleukin 2 and nuclear factor kappaB binding to DNA in activated T-lymphocytes, Biochem. J. 337 (Pt 2) (1999), pp. 269-274.
[35] A.T. Shamshiev, F. Ampenberger, B. Ernst, L. Rohrer, B.J. Marsland and M. Kopf, Dyslipidemia inhibits Toll-like receptor-induced activation of CD8alpha-negative dendritic cells and protective Th1 type immunity, J. Exp. Med. 204 (2007), pp. 441-452.
[36] J. Trueta and A.J. Buhr, The vascular contribution to osteogenesis. V. The vasculature supplying the epiphysial cartilage in rachitic rats, J. Bone Joint Surg. Br. 45 (1963), pp. 572-581.
[37] R. Havel, H. Eder and J. Bradgon, The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum, J. Clin. Invest. 34 (1955), pp. 1345-1353.
[38] I. Vermes, C. Haanen, H. Steffens-Nakken and C. Reutelingsperger, A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V, J. Immunol. Methods 184 (1995), pp. 39-51.
[39] B. Paigen, D. Mitchell, K. Reue, A. Morrow, A.J. Lusis and R.C. LeBoeuf, Ath-1, a gene determining atherosclerosis susceptibility and high density lipoprotein levels in mice, Proc. Natl. Acad. Sci. U. S. A. 84 (1987), pp. 3763-3767.
[40] B. Paigen, A. Morrow, C. Brandon, D. Mitchell and P. Holmes, Variation in susceptibility to atherosclerosis among inbred strains of mice, Atherosclerosis 57 (1985), pp. 65-73.
[41] F. Parhami, Y. Tintut, W.G. Beamer, N. Gharavi, W. Goodman and L.L. Demer, Atherogenic high-fat diet reduces bone mineralization in mice, J. Bone Miner. Res. 16 (2001), pp. 182-188.
[42] M.S. Huang, J. Lu, Y. Ivanov, A.P. Sage, W. Tseng, L.L. Demer and Y. Tintut, Hyperlipidemia impairs osteoanabolic effects of PTH, J. Bone Miner. Res. 23 (2008), pp. 1672-1679.
[43] C.M. Kitchen, Nonparametric vs parametric tests of location in biomedical research, Am. J. Ophthalmol. 147 (2009), pp. 571-572.
[44] L.E. Theill, W.J. Boyle and J.M. Penninger, RANK-L and RANK: T cells, bone loss, and mammalian evolution, Annu. Rev. Immunol. 20 (2002), pp. 795-823.
[45] J.D. Morrow and L.J. Roberts II, The isoprostanes. Current knowledge and directions for future research, Biochem. Pharmacol. 51 (1996), pp. 1-9.
[46] V.N. Bochkov, D. Mechtcheriakova, M. Lucerna, J. Huber, R. Malli, W.F. Graier, E. Hofer, B.R. Binder and N. Leitinger, Oxidized phospholipids stimulate tissue factor expression in human endothelial cells via activation of ERK/EGR-1 and Ca(++)/NFAT, Blood 99 (2002), pp. 199-206.
[47] J. Huber, V.N. Bochkov, B.R. Binder and N. Leitinger, The isoprostane 8-iso-PGE2 stimulates endothelial cells to bind monocytes via cyclic AMP- and p38 MAP kinase-dependent signaling pathways, Antioxid. Redox Signal. 5 (2003), pp. 163-169.
[48] M. Seyerl, S. Bluml, S. Kirchberger, V.N. Bochkov, O. Oskolkova, O. Majdic and J. Stockl, Oxidized phospholipids induce anergy in human peripheral blood T cells, Eur. J. Immunol. 38 (2008), pp. 778-787.
[49] R. Foncea, C. Carvajal, C. Almarza and F. Leighton, Endothelial cell oxidative stress and signal transduction, Biol. Res. 33 (2000), pp. 89-96.
[50] S. Bluml, S. Kirchberger, V.N. Bochkov, G. Kronke, K. Stuhlmeier, O. Majdic, G.J. Zlabinger, W. Knapp, B.R. Binder, J. Stockl and N. Leitinger, Oxidized phospholipids negatively regulate dendritic cell maturation induced by TLRs and CD40, J. Immunol. 175 (2005), pp. 501-508.
[51] T. Sawamura, N. Kume, T. Aoyama, H. Moriwaki, H. Hoshikawa, Y. Aiba, T. Tanaka, S. Miwa, Y. Katsura, T. Kita and T. Masaki, An endothelial receptor for oxidized low-density lipoprotein, Nature 386 (1997), pp. 73-77.
[52] R. Ohmori, Y. Momiyama, M. Nagano, H. Taniguchi, T. Egashira, A. Yonemura, H. Nakamura, K. Kondo and F. Ohsuzu, An oxidized low-density lipoprotein receptor gene variant is inversely associated with the severity of coronary artery disease, Clin. Cardiol. 27 (2004), pp. 641-644.
[53] M. Tatsuguchi, M. Furutani, J. Hinagata, T. Tanaka, Y. Furutani, S. Imamura, M. Kawana, T. Masaki, H. Kasanuki, T. Sawamura and R. Matsuoka, Oxidized LDL receptor gene (OLR1) is associated with the risk of myocardial infarction, Biochem. Biophys. Res. Commun. 303 (2003), pp. 247-250.
[54] H. Moriwaki, N. Kume, H. Kataoka, T. Murase, E. Nishi, T. Sawamura, T. Masaki and T. Kita, Expression of lectin-like oxidized low density lipoprotein receptor-1 in human and murine macrophages: upregulated expression by TNF-alpha, FEBS Lett. 440 (1998), pp. 29-32.
[55] Y. Hara, Y. Kusumi, M. Mitsumata, X.K. Li and M. Fujino, Lysophosphatidylcholine upregulates LOX-1, chemokine receptors, and activation-related transcription factors in human T-cell line Jurkat, J. Thromb. Thrombolysis (2007).
[56] G.K. Hansson, P. Libby, U. Schonbeck and Z.Q. Yan, Innate and adaptive immunity in the pathogenesis of atherosclerosis, Circ. Res. 91 (2002), pp. 281-291.
[57] F. Parhami, S. Jackson, Y. Tintut, V. Le, J. Balucan, M. Territo and L. Demer, Atherogenic diet and minimally oxidized low density lipoprotein inhibit osteogenic and promote adipogenic differentiation of marrow stromal cells, J. Bone Miner. Res. 14 (1999), pp. 2067-2078.
[58] P. von der Recke, M.A. Hansen and C. Hassager, The association between low bone mass at the menopause and cardiovascular mortality, Am. J. Med. 106 (1999), pp. 273-278.
[59] D.A. Towler, The osteogenic-angiogenic interface: novel insights into the biology of bone formation and fracture repair, Curr. Osteoporos. Rep. 6 (2008), pp. 67-71.
[60] S.J. Bensinger, M.N. Bradley, S.B. Joseph, N. Zelcer, E.M. Janssen, M.A. Hausner, R. Shih, J.S. Parks, P.A. Edwards, B.D. Jamieson and P. Tontonoz, LXR signaling couples sterol metabolism to proliferation in the acquired immune response, Cell 134 (2008), pp. 97-111.
[61] A. Boullier, Y. Li, O. Quehenberger, W. Palinski, I. Tabas, J.L. Witztum and Y.I. Miller, Minimally oxidized LDL offsets the apoptotic effects of extensively oxidized LDL and free cholesterol in macrophages, Arterioscler. Thromb. Vasc. Biol. 26 (2006), pp. 1169-1176.
[62] Y. Kuge, N. Kume, S. Ishino, N. Takai, Y. Ogawa, T. Mukai, M. Minami, M. Shiomi and H. Saji, Prominent lectin-like oxidized low density lipoprotein (LDL) receptor-1 (LOX-1) expression in atherosclerotic lesions is associated with tissue factor expression and apoptosis in hypercholesterolemic rabbits, Biol. Pharm. Bull 31 (2008), pp. 1475-1482.
[63] H. Satoh, E. Kiyota, Y. Terasaki, T. Sawamura, K. Takagi, H. Mizuta and M. Takeya, Expression and localization of lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) in murine and human placentas, J. Histochem. Cytochem. 56 (2008), pp. 773-784.
[64] T. Simopoulou, K.N. Malizos and A. Tsezou, Lectin-like oxidized low density lipoprotein receptor 1 (LOX-1) expression in human articular chondrocytes, Clin. Exp. Rheumatol. 25 (2007), pp. 605-612.
[65] M. Liang, P. Zhang and J. Fu, Up-regulation of LOX-1 expression by TNF-alpha promotes trans-endothelial migration of MDA-MB-231 breast cancer cells, Cancer Lett. 258 (2007), pp. 31-37.
[66] X.P. Chen, T.T. Zhang and G.H. Du, Lectin-like oxidized low-density lipoprotein receptor-1, a new promising target for the therapy of atherosclerosis?, Cardiovasc. Drug Rev. 25 (2007), pp. 146-161.
[67] G.J. Blake, N. Rifai, J.E. Buring and P.M. Ridker, Blood pressure, C-reactive protein, and risk of future cardiovascular events, Circulation 108 (2003), pp. 2993-2999. View Record in Scopus | Cited By in Scopus (113)
[68] A.D. Pradhan, J.E. Manson, N. Rifai, J.E. Buring and P.M. Ridker, C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus, JAMA 286 (2001), pp. 327-334.
[69] T. Kita, N. Kume, M. Minami, K. Hayashida, T. Murayama, H. Sano, H. Moriwaki, H. Kataoka, E. Nishi, H. Horiuchi, H. Arai and M. Yokode, Role of oxidized LDL in atherosclerosis, Ann. N.Y. Acad. Sci. 947 (2001), pp. 199-205 discussion 205-6.
[70] D. Steinberg, Low density lipoprotein oxidation and its pathobiological significance, J. Biol. Chem. 272 (1997), pp. 20963-20966.
[71] S. Yla-Herttuala, W. Palinski, M.E. Rosenfeld, S. Parthasarathy, T.E. Carew, S. Butler, J.L. Witztum and D. Steinberg, Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man, J. Clin. Invest. 84 (1989), pp. 1086-1095.
[72] I.S. Young and J. McEneny, Lipoprotein oxidation and atherosclerosis, Biochem. Soc. Trans. 29 (2001), pp. 358-362. View Record in Scopus | Cited By in Scopus (51)
[73] X. Zhou, A.K. Robertson, C. Hjerpe and G.K. Hansson, Adoptive transfer of CD4+ T cells reactive to modified low-density lipoprotein aggravates atherosclerosis, Arterioscler. Thromb. Vasc. Biol. 26 (2006), pp. 864-870. View Record in Scopus | Cited By in Scopus (21)
[74] R. Wu, R. Giscombe, G. Holm and A.K. Lefvert, Induction of human cytotoxic T lymphocytes by oxidized low density lipoproteins, Scand. J. Immunol. 43 (1996), pp. 381-384.
[75] D. Cruz, A.D. Watson, C.S. Miller, D. Montoya, M.T. Ochoa, P.A. Sieling, M.A. Gutierrez, M. Navab, S.T. Reddy, J.L. Witztum, A.M. Fogelman, T.H. Rea, D. Eisenberg, J. Berliner and R.L. Modlin, Host-derived oxidized phospholipids and HDL regulate innate immunity in human leprosy, J. Clin. Invest. 118 (2008), pp. 2917-2928.
[76] W. Chen, J.P. Gardner, M. Kimura, M. Brimacombe, X. Cao, S.R. Srinivasan, G.S. Berenson and A. Aviv, Leukocyte telomere length is associated with HDL cholesterol levels: the Bogalusa heart study, Atherosclerosis (2009).
[77] G. Tsirpanlis, S. Chatzipanagiotou, F. Boufidou, V. Kordinas, M. Zoga, F. Alevyzaki, K. Stamatelou, E. Frangou, L. Savva and C. Nicolaou, Serum oxidized low-density lipoprotein is inversely correlated to telomerase activity in peripheral blood mononuclear cells of haemodialysis patients, Nephrology (Carlton) 11 (2006), pp. 506-509.
[78] C. Delpierre, E. Bonnet, F. Marion-Latard, C. Aquilina, M. Obadia, B. Marchou, P. Massip, B. Perret and J. Bernard, Impact of HIV infection on total body composition in treatment-naive men evaluated by dual-energy X-ray absorptiometry comparison of 90 untreated HIV-infected men to 241 controls, J. Clin. Densitom. 10 (2007), pp. 376-380.
|
|
| |
| |
|
|
|
